<DOC>
<DOCNO>EP-0656896</DOCNO> 
<TEXT>
<INVENTION-TITLE>
NEW LEUKOTRIENE-B4 ANTAGONISTS, PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS
</INVENTION-TITLE>
<CLASSIFICATIONS>C07C6731	C07D31722	C07C69712	C07C6500	C07C6700	C07C51353	C07C23518	C07C51347	C07C5968	C07C69736	C07C5990	C07C5900	C07D21379	C07D21300	C07C6540	C07C6976	C07C23500	C07C6900	C07C6524	C07D31700	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07C	C07D	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07C	C07D	C07D	C07C	C07C	C07C	C07C	C07C	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07C67	C07D317	C07C69	C07C65	C07C67	C07C51	C07C235	C07C51	C07C59	C07C69	C07C59	C07C59	C07D213	C07D213	C07C65	C07C69	C07C235	C07C69	C07C65	C07D317	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Antagonists of the leukotrienes-B4 have formula (I), in which n is an integer between 2 and 5, X is a direct bond, 1 to 6 methylene units, an ortho-, meta- or para-substituted phenyl ring or a meta- or para-substituted pyridin ring; Y is a bond to a hydrogen atom and at the same time to a hydroxy group, an oxygen atom with a double bond or -O-CH2-CH2-O-; R1 and R2 stand for the rest OH, -O-(C1-C4)-alkyl, O-(C3-C6)-cycloalkyl, -O-(C6-C10)-aryl, -O-(C7-C12)-aralkyl, O-(CH2)-CO-(C6-C10)-aryl or the residue NHR3, in which R3 stands for hydrogen, (C1-C4)-alkyl, (C3-C6)-cycloalkyl or (C7-C12)-aralkyl. Also disclosed are the salts of said antagonists with physiologically tolerable bases and their cyclodextrin clathrates.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SCHERING AG
</APPLICANT-NAME>
<APPLICANT-NAME>
SCHERING AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BUCHMANN BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
EKERDT ROLAND
</INVENTOR-NAME>
<INVENTOR-NAME>
FROEHLICH WOLFGANG
</INVENTOR-NAME>
<INVENTOR-NAME>
GIESEN CLAUDIA
</INVENTOR-NAME>
<INVENTOR-NAME>
HEINDL JOSEF
</INVENTOR-NAME>
<INVENTOR-NAME>
SKUBALLA WERNER
</INVENTOR-NAME>
<INVENTOR-NAME>
BUCHMANN, BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
EKERDT, ROLAND
</INVENTOR-NAME>
<INVENTOR-NAME>
FROEHLICH, WOLFGANG
</INVENTOR-NAME>
<INVENTOR-NAME>
GIESEN, CLAUDIA
</INVENTOR-NAME>
<INVENTOR-NAME>
HEINDL, JOSEF
</INVENTOR-NAME>
<INVENTOR-NAME>
SKUBALLA, WERNER
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
The invention relates to leukotriene-B
4
 antagonists of formula I 

 
wherein 


n
is an integer from 2 to 5, 
X
is a direct bond, from 1 to 6 methylene units, an 
ortho-,
 meta- or para-substituted 
phenyl ring or a meta- or para-substituted pyridine ring, 
Y
is a bond to a hydrogen atom and at the same time to a hydroxy group, or is 
a doubly-bonded oxygen atom or -O-CH
2
-CH
2
-O-, 
each of R
1
 and R
2
is the radical OH, -O-(C
1
-C
4
)alkyl, -O-(C
3
-C
6
)cycloalkyl, 
-O-(C
6
-C
10
)aryl, -O-(C
7
-C
12
)aralkyl, -O-(CH
2
)-CO-(C
6
-C
10
)aryl or the radical 
NHR
3
 wherein R
3
 is hydrogen, (C
1
-C
4
)alkyl, (C
3
-C
6
)cycloalkyl or (C
7
-C
12
)-aralkyl, 
 
and salts thereof with physiologically tolerable bases and cyclodextrin clathrates 

thereof. 
Pharmaceutical preparations characterized by a content of leukotriene-B
4
 
antagonists of the general formula I according to patent claim 1. 
Process for the preparation of leukotriene-B
4
 antagonists of formula I, 
characterised in that a compound of formula II  

 

 
wherein X, R
1
 and R
2
 are as defined above, is reacted in a manner known 
per se
 
with a compound of formula III 


 
wherein n and Y are as defined above and Z may be either a halogen atom or a 

sulphonate, such as, for example, tosylate, mesylate or trifluorosulphonate, in the 
presence of caesium, lithium or potassium carbonate, and, optionally, protecting 

groups are split off, the methyl ketone is reduced, ester groups are hydrolysed, 
carboxy groups are esterified or resulting acids of formula I are reacted with organic 

or inorganic bases or with cyclodextrins. 
(E/Z)-3-{2-(3-Methoxycarbonylphenylmethyloxy)-6-[3-(4-(1 -methoxypropen-2-yl)-3-methoxy-2-propylphenoxy)-propoxy]-phenyl}-propanoic 

acid methyl ester. 
3-{2-(3-Methoxycarbonylphenylmethyloxy)-6-[3-(4-propen-2-yl)-3-methoxy-2-propylphenoxy)-propoxy]-phenyl}-propanoic 

acid methyl ester. 
(E/Z)-3-{2-(3-Carboxyphenylmethyloxy)-6-[3-(4-(1-methoxypropen-2-yl)-3-methoxy-2-propylphenoxy)-propoxy]-phenyl}-propanoic 

acid. 
3-{2-(3-Carboxyphenylmethyloxy)-6-[3-(4-propen-2-yl)-3-methoxy-2-propyl-phenoxy)-propoxy]-phenyl}-propanoic 

acid. 
</CLAIMS>
</TEXT>
</DOC>
